Clinical trials for lupus: Are we there yet?

Bulletin of the NYU Hospital for Joint Diseases

Volumn 67, Issue 3, 2009, Pages 267-270

  Merrill, Joan T ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ARTHRITIS; BIOLOGICAL THERAPY; CLINICAL TRIAL; DISEASE ACTIVITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; REVIEW; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HEALTH STATUS INDICATORS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATIENT SELECTION; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 70350180430     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Alarcón GS, McGwin G Jr, Petri M, et al. PROFILE Study Group Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus. 2002;11:95-101. (Pubitemid 34259439)
2. Merrill JT, Asherson RA. Catastrophic antiphospholipid syndrome. Nat Clin Pract Rheumatol. 2006 Feb;2(2):81-89
3. Merrill JT. The antiphospholipid syndrome and atherosclerosis: clues to pathogenesis. Curr Rheumatol Rep. 2003;5:401-406
4. Hanly JG, Urowitz MD, Siannis F, et al. Autoantibodies and neuropsychiatric events at diagnosis of SLE. Arthritis Rheum. 2008;58:843-853
5. Swigris JJ, Fischer A, Gillis J, et al. Pulmonary and thrombotic manifestations of systemic lupus erythematosus. Chest. 2008 Jan;133:271-280
6. Wislowska M, Dere D, Kochmaski M, et al. Systolic and diastolic heart function in SLE patients. Rheumatol Int. 2009 Mar 25; Epub ahead print.
7. Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 1999 42:51-60. (Pubitemid 29042570)
8. Urowitz MB, Ibaez D, Gladman DD. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol. 2007;34:70-75
9. Rubin LA, Urowitz MB, Gladman DD. Mortality in systemic lupus erythematosus: the bimodal pattern revisited. QJM. 1985;55:87-98.
10. Urowitz MB, Gladman D, Ibaez D, et al. Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis Rheum. 2008;59:176-180 (Pubitemid 351272951)
11. Shah MA, Shah AM, Krishnan EJ. Poor outcomes after acute myocardial infarction in systemic lupus erythematosus. J Rheumatol. 2009 Mar;36:570-575
12. Merrill JT. Regulation of the vasculature: clues from lupus. Curr Opin Rheumatol. 2002;4:504-509
13. Merrill JT. Lahita RG. Sex hormone binding globulins and atherosclerotic risk in systemic lupus. Lupus. 2000;9(3):217-22.
14. Merrill JT. Pathogenesis and treatment of the antiphospholipid syndrome. In: Lahita RG (ed). Systemic Lupus Erythematosus. New York: Academic Press, 1999.
15. Bertsias G, Gordon C, Boumpas DT. Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future - the EULAR recommendations for the management of SLE and the use of end-points in clinical trials. Lupus. 2008;17:437-442 (Pubitemid 351798723)
16. Merrill JT. Emergence of targeted immune therapies for systemic lupus. Expert Opin Emerg Drugs. 2005 Feb;10(1):53-65.
17. Merrill JT, Erkan D, Buyon JP. Challenges in bringing the bench to bedside in drug development for SLE. Nat Rev Drug Discov. 2004 Dec;3(12):1036-1046
18. Wollaston SJ, Farewell VT, Isenberg DA, et al. Systemic Lupus International Collaborating Clinics (SLICC). Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. J Rheumatol. 2004;31:2390-2394
19. Merrill JT. (Invited Editorial) Measuring disease activity in systemic lupus: progress and problems. J Rheumatol. 2002 Nov;29(11):2256-2257 (Pubitemid 35266012)
20. Mosca M, Merrill JT Bombardieri, S. Assessment of disease activity in SLE. In: Tsokos GC, Gordon C, Smolen JS (eds): Systemic Lupus Erythematosus: A Companion to Rheumatology. Philadelphia: Mosby Elsevier, 2006.
21. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the randomized, double-blind phase II/III study (EXPLORER). Program and abstracts of the American College of Rheumatology 2008 Annual Scientific Meeting; Oral presentation. October 24-29, 2008; San Francisco, California, Abstract L12.
22. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in SLE: results of a 12-month exploratory study. Program and abstracts of the American College of Rheumatology 2008 Annual Scientific Meeting; Oral presentation. October 24-29, 2008; San Francisco, California, Abstract L15.
23. López P, Gómez J, Prado C, et al. Influence of functional interleukin 10/tumor necrosis factor-alpha polymorphisms on interferon-alpha, IL-10, and regulatory T cell population in patients with systemic lupus erythematosus receiving antimalarial treatment. J Rheumatol. 2008;35:1473-1476
24. Sailler L, Puissant B, Méliani P, et al. Blood concentrations of hydroxychloroquine and its desethyl derivative correlate negatively with the percentage of CD45RO+ cells among CD4+ lymphocytes in hydroxychloroquine-treated lupus patients. Ann N Y Acad Sci. 2007 Jun;1108:41-50.
25. Wallace DJ, Linker-Israeli M, Hyun S, et al. The effect of hydroxychloroquine therapy on serum levels of immunoregula- tory molecules in patients with systemic lupus erythematosus. J Rheumatol. 1994;21:375-376 (Pubitemid 24078865)
26. Grootscholten C, Dieker JW, McGrath FD, et al. A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/ methylprednisolone. Ann Rheum Dis. 2007 May;66(5):693-696
27. Dejica D. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy. Roum Arch Microbiol Immunol. 2001 Jul-Sep;60(3):183-201.